Beta Drugs Ltd.
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
Market Cap & Net Worth: Beta Drugs Ltd. (BETA)
Beta Drugs Ltd. (NSE:BETA) has a market capitalization of $126.83 Million (₹10.98 Billion) as of March 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #25245 globally and #1323 in its home market, demonstrating a 1.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beta Drugs Ltd.'s stock price ₹1088.10 by its total outstanding shares 10094553 (10.09 Million).
Beta Drugs Ltd. Market Cap History: 2017 to 2026
Beta Drugs Ltd.'s market capitalization history from 2017 to 2026. Data shows growth from $21.83 Million to $126.83 Million (32.42% CAGR).
Beta Drugs Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beta Drugs Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BETA by Market Capitalization
Companies near Beta Drugs Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Beta Drugs Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Beta Drugs Ltd. Historical Marketcap From 2017 to 2026
Between 2017 and today, Beta Drugs Ltd.'s market cap moved from $21.83 Million to $ 126.83 Million, with a yearly change of 32.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹126.83 Million | -29.76% |
| 2025 | ₹180.56 Million | -22.89% |
| 2024 | ₹234.17 Million | +36.67% |
| 2023 | ₹171.34 Million | +107.04% |
| 2022 | ₹82.76 Million | +17.90% |
| 2021 | ₹70.19 Million | +405.84% |
| 2020 | ₹13.88 Million | +56.85% |
| 2019 | ₹8.85 Million | -0.78% |
| 2018 | ₹8.92 Million | -59.15% |
| 2017 | ₹21.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Beta Drugs Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.83 Million USD |
| MoneyControl | $126.83 Million USD |
| MarketWatch | $126.83 Million USD |
| marketcap.company | $126.83 Million USD |
| Reuters | $126.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.